An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Monash Health, Monash University, Alfred Health, The Alfred Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162685373
Cites:
Cited by:
Related to: